Literature DB >> 30967474

The cardiac syndecan-4 interactome reveals a role for syndecan-4 in nuclear translocation of muscle LIM protein (MLP).

Sabrina Bech Mathiesen1, Marianne Lunde1, Jan Magnus Aronsen1,2, Andreas Romaine1,3, Anita Kaupang1, Marita Martinsen1, Gustavo Antonio de Souza4, Tuula A Nyman4, Ivar Sjaastad1,3, Geir Christensen1,3, Cathrine Rein Carlson5.   

Abstract

Costameres are signaling hubs at the sarcolemma and important contact points between the extracellular matrix and cell interior, sensing and transducing biomechanical signals into a cellular response. The transmembrane proteoglycan syndecan-4 localizes to these attachment points and has been shown to be important in the initial stages of cardiac remodeling, but its mechanistic function in the heart remains insufficiently understood. Here, we sought to map the cardiac interactome of syndecan-4 to better understand its function and downstream signaling mechanisms. By combining two different affinity purification methods with MS analysis, we found that the cardiac syndecan-4 interactome consists of 21 novel and 29 previously described interaction partners. Nine of the novel partners were further validated to bind syndecan-4 in HEK293 cells (i.e. CAVIN1/PTRF, CCT5, CDK9, EIF2S1, EIF4B, MPP7, PARVB, PFKM, and RASIP). We also found that 19 of the 50 interactome partners bind differently to syndecan-4 in the left ventricle lysate from aortic-banded heart failure (ABHF) rats compared with SHAM-operated animals. One of these partners was the well-known mechanotransducer muscle LIM protein (MLP), which showed direct and increased binding to syndecan-4 in ABHF. Nuclear translocation is important in MLP-mediated signaling, and we found less MLP in the nuclear-enriched fractions from syndecan-4-/- mouse left ventricles but increased nuclear MLP when syndecan-4 was overexpressed in a cardiomyocyte cell line. In the presence of a cell-permeable syndecan-4-MLP disruptor peptide, the nuclear MLP level was reduced. These findings suggest that syndecan-4 mediates nuclear translocation of MLP in the heart.
© 2019 Mathiesen et al.

Entities:  

Keywords:  biomechanics; cardiomyopathy; cysteine and glycine rich protein 3 (CSRP3); heart; muscle LIM protein (MLP); nuclear translocation; protein complex; protein–protein interaction; proteoglycan; syndecan-4

Mesh:

Substances:

Year:  2019        PMID: 30967474      PMCID: PMC6552415          DOI: 10.1074/jbc.RA118.006423

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Development of simple and rapid elution methods for proteins from various affinity beads for their direct MALDI-TOF downstream application.

Authors:  Patrik Mlynarcik; Elena Bencurova; Marian Madar; Rastislav Mucha; Lucia Pulzova; Stanislav Hresko; Mangesh Bhide
Journal:  J Proteomics       Date:  2012-03-13       Impact factor: 4.044

2.  Syndecan-4 regulates subcellular localization of mTOR Complex2 and Akt activation in a PKCalpha-dependent manner in endothelial cells.

Authors:  Chohreh Partovian; Rong Ju; Zhen W Zhuang; Kathleen A Martin; Michael Simons
Journal:  Mol Cell       Date:  2008-10-10       Impact factor: 17.970

Review 3.  Cardiac Z-disc signaling network.

Authors:  Derk Frank; Norbert Frey
Journal:  J Biol Chem       Date:  2011-01-21       Impact factor: 5.157

4.  Multimerization of the cytoplasmic domain of syndecan-4 is required for its ability to activate protein kinase C.

Authors:  E S Oh; A Woods; J R Couchman
Journal:  J Biol Chem       Date:  1997-05-02       Impact factor: 5.157

5.  Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C.

Authors:  E S Oh; A Woods; J R Couchman
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

6.  Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy.

Authors:  Christian Geier; Andreas Perrot; Cemil Ozcelik; Priska Binner; Damian Counsell; Katrin Hoffmann; Bernhard Pilz; Yvonne Martiniak; Katja Gehmlich; Peter F M van der Ven; Dieter O Fürst; Arnold Vornwald; Eberhard von Hodenberg; Peter Nürnberg; Thomas Scheffold; Rainer Dietz; Karl Josef Osterziel
Journal:  Circulation       Date:  2003-03-18       Impact factor: 29.690

Review 7.  Syndecan-4 signaling at a glance.

Authors:  Arye Elfenbein; Michael Simons
Journal:  J Cell Sci       Date:  2013-08-22       Impact factor: 5.285

8.  Syndecan-4 Regulates Muscle Differentiation and Is Internalized from the Plasma Membrane during Myogenesis.

Authors:  Sissel B Rønning; Cathrine R Carlson; Espen Stang; Svein O Kolset; Kristin Hollung; Mona E Pedersen
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

9.  Inhibition of nuclear import of calcineurin prevents myocardial hypertrophy.

Authors:  Matthias Hallhuber; Natalie Burkard; Rongxue Wu; Mamta H Buch; Stefan Engelhardt; Lutz Hein; Ludwig Neyses; Kai Schuh; Oliver Ritter
Journal:  Circ Res       Date:  2006-08-24       Impact factor: 17.367

10.  Cardiomyocytes Sense Matrix Rigidity through a Combination of Muscle and Non-muscle Myosin Contractions.

Authors:  Pragati Pandey; William Hawkes; Junquiang Hu; William Valentine Megone; Julien Gautrot; Narayana Anilkumar; Min Zhang; Liisa Hirvonen; Susan Cox; Elisabeth Ehler; James Hone; Michael Sheetz; Thomas Iskratsch
Journal:  Dev Cell       Date:  2018-01-26       Impact factor: 12.270

View more
  6 in total

1.  Cardiomyocyte-specific overexpression of syndecan-4 in mice results in activation of calcineurin-NFAT signalling and exacerbated cardiac hypertrophy.

Authors:  Ida G Lunde; J Magnus Aronsen; A Olav Melleby; Mari E Strand; Jonas Skogestad; Bård A Bendiksen; M Shakil Ahmed; Ivar Sjaastad; Håvard Attramadal; Cathrine R Carlson; Geir Christensen
Journal:  Mol Biol Rep       Date:  2022-10-07       Impact factor: 2.742

2.  AKAP18δ Anchors and Regulates CaMKII Activity at Phospholamban-SERCA2 and RYR.

Authors:  Cathrine R Carlson; Jan Magnus Aronsen; Anna Bergan-Dahl; Marie Christine Moutty; Marianne Lunde; Per Kristian Lunde; Hilde Jarstadmarken; Pimthanya Wanichawan; Laetitia Pereira; Terje R S Kolstad; Bjørn Dalhus; Hariharan Subramanian; Susanne Hille; Geir Christensen; Oliver J Müller; Viacheslav Nikolaev; Donald M Bers; Ivar Sjaastad; Xin Shen; William E Louch; Enno Klussmann; Ole M Sejersted
Journal:  Circ Res       Date:  2021-11-24       Impact factor: 23.213

3.  Syndecan-4-/- Mice Have Smaller Muscle Fibers, Increased Akt/mTOR/S6K1 and Notch/HES-1 Pathways, and Alterations in Extracellular Matrix Components.

Authors:  Sissel Beate Rønning; Cathrine Rein Carlson; Jan Magnus Aronsen; Addolorata Pisconti; Vibeke Høst; Marianne Lunde; Kristian Hovde Liland; Ivar Sjaastad; Svein Olav Kolset; Geir Christensen; Mona Elisabeth Pedersen
Journal:  Front Cell Dev Biol       Date:  2020-07-31

Review 4.  What Are the Potential Roles of Nuclear Perlecan and Other Heparan Sulphate Proteoglycans in the Normal and Malignant Phenotype.

Authors:  Anthony J Hayes; James Melrose
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

5.  Proteomic analysis reveals exercise training induced remodelling of hepatokine secretion and uncovers syndecan-4 as a regulator of hepatic lipid metabolism.

Authors:  William De Nardo; Paula M Miotto; Jacqueline Bayliss; Shuai Nie; Stacey N Keenan; Magdalene K Montgomery; Matthew J Watt
Journal:  Mol Metab       Date:  2022-04-02       Impact factor: 8.568

6.  The female syndecan-4-/- heart has smaller cardiomyocytes, augmented insulin/pSer473-Akt/pSer9-GSK-3β signaling, and lowered SCOP, pThr308-Akt/Akt and GLUT4 levels.

Authors:  Thea Parsberg Støle; Marianne Lunde; Xin Shen; Marita Martinsen; Per Kristian Lunde; Jia Li; Francesca Lockwood; Ivar Sjaastad; William Edward Louch; Jan Magnus Aronsen; Geir Christensen; Cathrine Rein Carlson
Journal:  Front Cell Dev Biol       Date:  2022-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.